webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Exatecan hydrochloride

  CAS No.: 144008-87-7   Cat No.: BADC-01405   Purity: ≥95% 4.5  

Exatecan hydrochloride is the salt of Exatecan, which is a semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan is an inhibitor of DNA topoisomerase I.

Exatecan hydrochloride

Structure of 144008-87-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C24H22FN3O4.HCl
Molecular Weight
471.91

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, monohydrochloride, (1S,9S)-; 10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, monohydrochloride, (1S-trans)-; DX 8951a; (1S,9S)-1-Amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione hydrochloride (1:1)
IUPAC Name
(10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione;hydrochloride
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C5C(CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O.Cl
InChI
InChI=1S/C24H22FN3O4.ClH/c1-3-24(31)14-6-18-21-12(8-28(18)22(29)13(14)9-32-23(24)30)19-16(26)5-4-11-10(2)15(25)7-17(27-21)20(11)19;/h6-7,16,31H,3-5,8-9,26H2,1-2H3;1H/t16-,24-;/m0./s1
InChIKey
LKVSRDWTZFISCX-GRGFAMGGSA-N

Exatecan hydrochloride is an innovative compound utilized in the field of oncology, recognized for its potential to inhibit the proliferation of cancer cells. As a semisynthetic derivative of camptothecin, Exatecan offers enhanced solubility and bioavailability, making it a viable candidate for therapeutic applications. This compound operates as a DNA topoisomerase I inhibitor, a mechanism vital for the interruption of DNA replication in cancer cells. The specificity of Exatecan to the target enzyme ensures its effectiveness in minimizing the growth and spread of malignant cells in various types of cancer. By mitigating the replication of cancerous cells, Exatecan hydrochloride holds significant promise in the provision of effective cancer treatments, showcasing its potential as a cornerstone in antineoplastic therapy.

The discovery and development of Exatecan hydrochloride have been pivotal in advancing cancer treatment methodologies. The inhibition of DNA topoisomerase I by Exatecan is crucial, as this enzyme is responsible for unwinding the DNA helix during replication. Inhibiting this process hampers the necessary DNA functions essential for cell division in tumor cells, thus arresting their growth. Researchers have focused on modifying camptothecin, the natural precursor of Exatecan, to improve its clinical applicability. Through meticulous research and chemical modification, Exatecan has emerged with improved therapeutic properties, allowing it to penetrate cancer cells more efficiently and resist metabolic degradation. These properties enhance the compound’s effectiveness and safety profile, marking a significant step forward in oncological pharmaceutics.

In drug discovery, Exatecan hydrochloride serves as a paradigm for designing drugs that can selectively target and terminate cancerous cells without causing extensive harm to normal tissues. The process of optimizing Exatecan has elucidated pathways for developing other topoisomerase inhibitors, offering insights into structure-activity relationships that could inform future drug discovery processes. The ongoing research into fine-tuning Exatecan derivatives underscores the compound’s flexibility and potential for broader application, possibly extending beyond oncology into other fields requiring precise inhibition of cellular replication mechanisms.

Furthermore, the clinical application of Exatecan hydrochloride has substantially influenced treatment strategies for specific cancer types, including metastatic breast cancer and small-cell lung cancer. Given its potent activity and specificity, Exatecan, often used in combination with other chemotherapy agents, augments the therapeutic index of cancer treatments, thereby improving patient outcomes. Clinical trials continually explore optimal dosing regimens and combinations, reaffirming its role in personalized medicine. By integrating Exatecan hydrochloride into treatment protocols, medical professionals are better equipped to devise individualized treatment plans that maximize efficacy while minimizing adverse effects, embodying the essence of tailored cancer therapy.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: NH2-PEG4-VC-PAB-DMEA-SN38 | Cantuzumab mertansine | SC-VC-PAB-DM1 | SPDB-DM1 | DM1-SPP | Lys-SMCC-DM1 | Daunorubicin hydrochloride | MC-DM1 | CL2-SN-38 | Val-Cit-PAB-MMAE | Exatecan hydrochloride
Send Inquiry
Verification code
Inquiry Basket